Welcome to our dedicated page for Caribou Biosciences SEC filings (Ticker: CRBU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Caribou Biosciences, Inc. (Nasdaq: CRBU) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including Forms 10-K, 10-Q, 8-K, and other Exchange Act reports. As a clinical-stage CRISPR genome-editing biopharmaceutical company, Caribou uses these filings to report on its financial condition, clinical development progress, and key corporate events.
Current and periodic reports such as Forms 10-Q and 10-K contain management’s discussion of operating results, research and development spending on allogeneic CAR-T programs like vispacabtagene regedleucel (vispa-cel; formerly CB-010) and CB-011, and information about licensing and collaboration revenue. These filings also describe risk factors associated with developing allogeneic CAR-T cell therapies, the company’s dependence on clinical trial outcomes, and its capital resources.
Form 8-K filings are especially relevant for tracking material events at Caribou. Recent 8-Ks have furnished press releases announcing quarterly financial results and business updates, preliminary cash and investment balances, and detailed clinical data from the ANTLER phase 1 trial of vispa-cel and the CaMMouflage phase 1 trial of CB-011. An 8-K dated June 18, 2025, also documents Nasdaq’s notice that Caribou regained compliance with the minimum bid price requirement under Listing Rule 5450(a)(1).
Investors interested in regulatory strategy and designations can use these filings to review discussions of RMAT, Fast Track, and Orphan Drug designations for vispa-cel and CB-011, as well as the company’s description of a planned randomized, controlled pivotal phase 3 trial for vispa-cel in second-line large B cell lymphoma.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify important disclosures on clinical data, cash runway, and Nasdaq listing status. Real-time updates from EDGAR, along with access to current and historical 8-Ks and other reports, support deeper analysis of CRBU’s regulatory and financial history.
Caribou Biosciences (CRBU) filed its Q3 2025 10‑Q, showing licensing and collaboration revenue of $2.198 million and a net loss of $27.548 million for the quarter. For the nine months ended September 30, revenue was $7.218 million with a net loss of $121.637 million. Operating cash used year‑to‑date was $90.168 million.
Cash, cash equivalents, and marketable securities totaled $159.212 million as of September 30, 2025, and management expects this to fund operations for at least the next 12 months. The company recorded $12.150 million of impairment charges and a $9.158 million impairment of an equity investment year‑to‑date, and reduced an MSKCC success payments liability to zero following license termination. Restructuring actions included discontinuing two programs and a workforce reduction of about 32%, with $1.8 million in severance and $0.4 million in wind‑down costs.
Clinical updates highlighted vispa‑cel (CD19): in a 22‑patient confirmatory cohort, overall response rate was 82% with a 64% complete response and 51% 12‑month progression‑free survival. An optimized 35‑patient cohort showed an 86% overall response and 63% complete response. The company plans a randomized pivotal phase 3 evaluation in second‑line LBCL.
Caribou Biosciences (CRBU) furnished an 8‑K announcing it issued a press release with financial results for the quarter ended September 30, 2025, and a business update. The press release is included as Exhibit 99.1 and is incorporated by reference.
The company states the information under Item 2.02, including Exhibit 99.1, is being furnished and not deemed “filed” under the Exchange Act.
Caribou Biosciences (CRBU) reported preliminary cash, cash equivalents, and marketable securities of $159.2 million as of September 30, 2025. The company also released new clinical data for its allogeneic CAR-T programs and outlined a pivotal plan for vispacabtagene regedleucel (vispa-cel).
In the ANTLER phase 1 trial’s 2L LBCL confirmatory cohort (N=22) with partial HLA matching and dosing at 80x10^6 cells, vispa-cel showed an 82% overall response rate (18/22), 64% complete response (14/22), and 51% 12‑month PFS at a 6.0‑month median follow-up. An optimized cohort (N=35) reported 86% ORR (30/35), 63% CR (22/35), and 53% 12‑month PFS at 11.8 months’ median follow‑up. Safety showed common TEAEs typical of CAR‑T; there were no GvHD cases, no grade ≥3 ICANS, fewer than 5% grade ≥3 CRS, and one vispa‑cel–related grade 5 IEC‑HS.
The company plans a randomized, controlled pivotal phase 3 in approximately 250 2L LBCL CD19‑naïve patients ineligible for transplant and autologous CAR‑T, with PFS as the primary endpoint. In multiple myeloma, CB‑011 dose escalation identified a recommended dose (450x10^6); in a 12‑patient BCMA‑naïve cohort at this dose, responses included 92% ORR (11/12), 75% CR/sCR (9/12), and 91% (10/11) MRD‑negativity at 8.3 months’ median follow‑up, with a manageable safety profile.
Caribou Biosciences reported a quarterly net loss of $54.1 million and a six-month net loss of $94.1 million, with licensing and collaboration revenue of $2.7 million for the quarter and $5.0 million for the six months ended June 30, 2025. Management reported cash, cash equivalents and marketable securities of $183.9 million as of June 30, 2025, which it expects will fund operations for at least the next 12 months.
The company announced a strategic pipeline prioritization that discontinues preclinical research and two programs (GALLOP and AMpLify) and reduced the workforce by 47 employees (~32%). It recorded $12.15 million of impairment charges and a $9.16 million impairment of its equity investment in Edge, remeasured the MSKCC success payments liability to zero following termination notice, and ended the quarter with total assets of $220.9 million and an accumulated deficit of $542.5 million.
Caribou Biosciences, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025 and provided a business update. The press release is attached as Exhibit 99.1 to this Current Report and is incorporated by reference into the disclosure.
The filing specifies that the Item 2.02 information (including Exhibit 99.1) is being furnished and therefore is not deemed "filed" under the Exchange Act, meaning it is provided for investor information without extending Section 18 liabilities. The 8-K itself does not include separate financial tables or statements beyond the furnished press release.